BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
· Financial Post
SAN CARLOS, Calif. -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Read More
Visit newsbetting.club for more information.